Oligonucleotide Therapy Market Size is valued at USD 5.21 billion in 2023 and is predicted to reach USD 19.92 billion by the year 2031 at a 18.6% CAGR during the forecast period for 2024-2031.
Oligonucleotides are some of the most promising therapeutic mechanisms for a range of hard-to-treat diseases, in particular those caused by genetic mutations. These are Short sequences of artificially created DNA or RNA molecules that attach to matching sequences in messenger RNA or proteins found in specific cells. Subcategories encompass antisense oligonucleotides (ASOs), aptamer RNAs, and RNA interference (RNAi) oligonucleotides. Several pharmaceutical companies were investigating oligonucleotide therapy, a treatment approach that utilizes chemically manufactured small molecule medications resembling nucleotides. These therapies have the potential to exhibit a similar level of specificity as therapeutic antibodies. Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate the cell membrane when administered on their own.
The market for oligonucleotide treatments has grown significantly due to developments in drug delivery technology, nucleic acid chemistry, and a better knowledge of the molecular causes of disease. Antisense oligonucleotides, small interfering RNA (siRNA), microRNA (miRNA) mimics or inhibitors, aptamers, and oligonucleotide-based gene editing tools like CRISPR-Cas9 are important oligonucleotide-based treatment modalities.
The Oligonucleotide Therapy Market is segmented on the basis of type, application and end-user. Based on type, the oligonucleotide therapy market is segmented into antisense, ribozymes, aptamers, miRNA, CpG/Immunostimulatory, and RNAi. Based on application, the oligonucleotide therapy market is segmented into infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases and others. The End User segment consists of Hospitals, Research Institutes, and Others.
The antisense oligonucleotide segment is expected to hold the largest share of the market. This segment's benefit is due to the optimization of enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxicity. Antisense oligonucleotide (ASO) therapies have developed into a prominent class of therapeutics. The antisense oligonucleotide segment of the oligonucleotide therapy market is witnessing unique growth due to its potential to target specific disease-causing genes at the molecular level. Antisense oligonucleotides offer a promising approach for treating genetic disorders, neurological diseases, and various types of cancers by modulating gene expression. Advancements in oligonucleotide chemistry, delivery systems, and personalized medicine are driving the development of novel antisense therapies. With ongoing research as well as clinical trials demonstrating the efficacy and safety of antisense oligonucleotides, this segment is poised for continued expansion and adoption in the field of precision medicine and targeted therapeutics.
Neurodegenerative disorders are indeed a significant focus within the oligonucleotide therapy market segment. The development of oligonucleotide-based therapies for conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease is gaining momentum. The potential of oligonucleotide therapy to target specific genes and pathways involved in neurodegeneration has sparked interest in addressing these challenging conditions. As research progresses and clinical trials advance, the neurodegenerative disorders segment is expected to play a crucial role in driving innovation & growth within the oligonucleotide therapy market.
The North American oligonucleotide therapy market is experiencing robust growth driven by major factors such as increasing research and development activities, rising investments in biotechnology and pharmaceutical sectors, and a growing focus on precision medicine. The region's well-established healthcare infrastructure, strong regulatory framework, and presence of market players contribute to market expansion. Ongoing advancements in oligonucleotide chemistry, delivery technologies, and personalized medicine are shaping the landscape of oligonucleotide therapies in North America. In addition, Asia Pacific is projected to grow at a rapid rate in the global Oligonucleotide Therapy Market due to growing healthcare concerns, especially in the aging population.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 5.21 Bn |
|
Revenue Forecast In 2031 |
USD 19.92 Bn |
|
Growth Rate CAGR |
CAGR of 18.6% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
BPCI Biotech Holding, SomaGenics Inc, Hepion Pharmaceuticals, Alnylam Pharmaceuticals, Regulus Therapeutics Inc, Ionis Pharmaceuticals, Gilead Sciences, Inc, Santaris, InteRNA Technologies B.V., Mirage, Biogen, Merck KgaA, Pfizer Inc. and Others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Oligonucleotide Therapy Market Snapshot
Chapter 4. Global Oligonucleotide Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Antisense
5.2.2. Ribozymes
5.2.3. Aptamers
5.2.4. miRNA
5.2.5. CpG/Immunostimulatory
5.2.6. RNAi
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Infectious Diseases
6.2.2. Oncology
6.2.3. Neurodegenerative Disorders
6.2.4. Cardiovascular Diseases
6.2.5. Kidney Diseases
6.2.6. Others
Chapter 7. Market Segmentation 3: by End Users Estimates & Trend Analysis
7.1. by End Users & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End Users:
7.2.1. Hospitals
7.2.2. Research Institutes
7.2.3. Others
Chapter 8. Oligonucleotide Therapy Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.1.2. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.1.3. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.1.4. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.2. Europe
8.2.1. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.2.2. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.2.3. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.2.4. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.3.2. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.3.3. Asia-Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.3.4. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.4. Latin America
8.4.1. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.4.2. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.4.3. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.4.4. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
8.5.2. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
8.5.3. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031
8.5.4. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. BPCI Biotech Holding
9.2.2. SomaGenics Inc.
9.2.3. Hepion Pharmaceuticals
9.2.4. Alnylam Pharmaceuticals
9.2.5. Regulus Therapeutics Inc.
9.2.6. Ionis Pharmaceuticals
9.2.7. Gilead Sciences Inc.
9.2.8. Santaris
9.2.9. InteRNA Technologies B.V.
9.2.10. Mirage
9.2.11. Biogen
9.2.12. Merck KGaA
9.2.13. Pfizer Inc.
9.2.14. Other Prominent Players
Oligonucleotide Therapy Market By Type-
Oligonucleotide Therapy Market By Application-
Oligonucleotide Therapy Market By End-User-
Oligonucleotide Therapy Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
